Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study

Ophthalmology

Volumn 121, Issue 5, 2014, Pages 1045-1053

  Schmidt Erfurth, Ursula ^a   Lang, Gabriele E ^b   Holz, Frank G ^c   Schlingemann, Reinier O ^d,e   Lanzetta, Paolo ^f,g   Massin, Pascale ^h   Gerstner, Ortrud ⁱ   Bouazza, Abdelkader Si ⁱ   Shen, Haige ^j   Osborne, Aaron ⁱ   Mitchell, Paul ^k  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^f UNIVERSITY OF UDINE   (Italy)

^g Istituto Europeo di Microchirurgia Oculare   (Italy)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j Novartis Beijing Novartis Pharma Co Ltd   (China)

^k UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; BACKACHE; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRY EYE; EPIPHORA; EYE PAIN; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RETINA MACULOPATHY; RHINOPHARYNGITIS; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; QUESTIONNAIRES; RETINA; RETREATMENT; SICKNESS IMPACT PROFILE; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84899902749     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.11.041     Document Type: Article

References (19)

1. T.A. Ciulla, A.G. Amador, and B. Zinman Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies Diabetes Care 26 2003 2653 2664
2. Fu AD, Yang SS, McDonald HR. The clinical management of diabetic retinopathy. Adv Stud Ophthalmol. October 2004:18-29. Available at: http://www.jhasio.com/template.cfm?TEMPLATE=include-programinfo.cfm&ID= 4&ZoneID=10&TYPE=text. Accessed November 24, 2013.
3. J.G. Dowler Laser management of diabetic retinopathy J R Soc Med 96 2003 277 279
4. N. Ferrara, L. Damico, and N. Shams et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
5. Lucentis. Summary of product characteristics. Section 4.1 Therapeutic indications. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000715/WC500043546.pdf. Accessed November 24, 2013.
6. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
7. Diabetic Retinopathy Clinical Research Network Writing Committee M.J. Elman, N.M. Bressler, and H. Qin et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
8. Q.D. Nguyen, S.M. Shah, A.A. Khwaja READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study Ophthalmology 117 2010 2146 2151
9. Diabetic Retinopathy Clinical Research Network M.J. Elman, H. Qin, and L.P. Aiello et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
10. D.V. Do, Q.D. Nguyen, A.A. Khwaja READ-2 Study Group Ranibizumab for Edema of the Macula in Diabetes study: 3-year outcomes and the need for prolonged frequent treatment JAMA Ophthalmol 131 2013 139 145
11. P. Mitchell, F. Bandello, U. Schmidt-Erfurth RESTORE Study Group The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
12. G.E. Lang, A. Berta, B.M. Eldem RESTORE Extension Study Group Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE Extension Study Ophthalmology 120 2013 2004 2012
13. N. Witt, T.Y. Wong, and A.D. Hughes et al. Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke Hypertension 47 2006 975 981
14. N. Patton, T. Aslam, and T. MacGillivray et al. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures J Anat 206 2005 319 348
15. P. Massin, F. Bandello, and J.G. Garweg et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2010 2399 2405
16. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
17. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
18. D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 2011 1594 1602
19. P.A. Campochiaro, D.M. Brown, and C.C. Awh et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049